Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer drug for

Polymer-based colloidal drug delivery carriers include polymeric micelles, nano- and micro- particles, or coated particles, and hydrogels [886,890,891]. These are being developed for vaccines and anti-cancer drugs, for targeting of specific treatment sites within the body, and as vehicles for ophthalmic and oral delivery. Methods for the creation of multi-layer coatings are reviewed by Sukhorukov [892] (see also Figure 14.4). Numerous examples are cited by Ravi Kumar [893]. [Pg.330]

A number of purine and pyrimidine analogs are useful as anti-cancer drugs. For example, 5-fluorouracil blocks the enzyme that produces thymidine, a key base in DNA, and kills many cancer cells as well as some healthy cells. [Pg.733]

There are several potent inhibitors of DHFR. One of them is methotrexate. Figure 1.5 shows methotrexate (color) both unbound (left) and bound (right) to DHFR (black and white). Methotrexate has been administered as an effective cytostatic cancer drug for over two decades. [Pg.28]

Fig. 5.3 Radiolabeling of anti-cancer drugs for pharmacokinetic studies. DACA, /V-[2-(dimethyl-ami no)]acridine-4-carboxamide. Fig. 5.3 Radiolabeling of anti-cancer drugs for pharmacokinetic studies. DACA, /V-[2-(dimethyl-ami no)]acridine-4-carboxamide.
Domb A, Bogdansky S, Olivi A, Judy K, Dureza C, Denartz D, Pinn MI, Colvin M, Brem H. Controlled dehvery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. Polymer Preprints 1991 32 21 -220. [Pg.370]

Some important applications of polymersomes span from imaging of tissues in vivo using near-infrared emissive polymersomes (NIR-polymersomes) [116], to the encapsulation of proteins, DNA and anti-cancer drugs for delivery applications. With... [Pg.141]

Following its initial publication. The New Scientist later editorialized, "The drug may yet live up to its promise as an anti-cancer agent - clinical trials are expected to start soon. It may even spawn an entirely new class of anti-cancer drugs. For now, however, it remains experimental, never yet properly tested in a person with cancer. People who self-administer the drug are taking a very long shot and, unlikely as it may sound, could even make their health worse."... [Pg.86]

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol levels and cardiovascular morbidity and mortality. Statins inhibit cancer cell proliferation in in vivo tumor growth in animal models (Campbell et al. 2006 Kusama et al. 2002 Paragh et al. 2003 Sivaprasad et al. 2006). Moreover, they increased iNOS mRNA and protein expression in the human breast adenocarcinoma cell line (MCF-7). NO cytotoxicity and tumor cell cytotoxicity were inhibited by iNOS inhibitors (Kotamraju et al. 2007). Based on these data, statins which are well known as a class of hyperlipidemic blockbuster drugs and are routinely used for lowering serum cholesterol levels are potential cancer drugs for use as NO inducers. [Pg.109]

Yart A, Mayeux P, Raynal P (2003) Gabl, SHP-2 and Other Novel Regulators of Ras Targets for Anticancer Drug Discovery. Curr Cancer Drug Targets 3 177-192... [Pg.19]

PTKs have been implicated in the regulation of a variety of biological responses such as cell proliferation, migration, differentiation, and survival. They have been demonstrated to play significant roles in the development of many disease states, including immunodeficiency, atherosclerosis, psoriasis, osteoporosis, diabetes, and cancer. In recent clinical trials impressive antitumor effects of PTK inhibitors have been observed. In future, PTK inhibitors may therefore become important drugs for the treatment of specific cancers. [Pg.1258]

Garrett, M. D. Workman, P. Discovering novel chemotherapeutic drugs for the third millennium. Fur. J. Cancer 1999, 35, 2010-2030. [Pg.263]

Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004 4(4) 345-354. [Pg.290]

One of the most successful conjugate polymer systems was developed by Duncan and Kopecek (25). The polymer carrier used in their system is poly [N(2-hydroxypropyl) methacrylamide] a biocompatible polymer that was originally developed as a plasma extender. They have evaluated a number of polymer conjugated drugs for cancer chemotherapy with interesting results. The attachment of the drug is through a peptidyl spacer pendent to the polymer backbone. These peptides links are stable in aqueous media but are readily hydrolyzed intracellularly... [Pg.14]


See other pages where Cancer drug for is mentioned: [Pg.248]    [Pg.1524]    [Pg.695]    [Pg.266]    [Pg.462]    [Pg.127]    [Pg.248]    [Pg.1524]    [Pg.695]    [Pg.266]    [Pg.462]    [Pg.127]    [Pg.62]    [Pg.72]    [Pg.75]    [Pg.77]    [Pg.167]    [Pg.203]    [Pg.7]    [Pg.78]    [Pg.1192]    [Pg.1256]    [Pg.1257]    [Pg.2]    [Pg.465]    [Pg.180]    [Pg.527]    [Pg.17]    [Pg.131]    [Pg.264]    [Pg.303]    [Pg.307]    [Pg.424]    [Pg.70]    [Pg.80]    [Pg.83]    [Pg.85]    [Pg.143]    [Pg.693]   


SEARCH



Drug Delivery for Cancer Therapy

For Cancer

Platinum and Palladium Drugs for Cancer Treatments

© 2024 chempedia.info